Gastroparesis affects the spontaneous movement of muscles (motility) in the stomach. Gastroparesis can interfere with normal digestion and cause nausea, vomiting, and abdominal pain. It causes problems with blood sugar levels and nutrition. Dietary changes and medical treatment can help control the condition. Medications such as domperidone, erythromycin, anti-emetics, and others are used to treat gastroparesis condition.
The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% during the forecast period (2022-2030).
Figure 1. Global Gastroparesis Treatment Market in Terms of Value (US$ million), By Region, 2022
An increase in the number of pipeline products is estimated to drive the global gastroparesis treatment market growth during the forecast period.
|Base Year:||2021||Market Size in 2022:||US$ 8,061.9 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||3.6%||2030 Value Projection:||US$ 10,726.0 Mn|
Processa Pharmaceuticals, Inc., EVOKE PHARMA , Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals
|Restraints & Challenges:||
Figure 2. Global Gastroparesis Treatment Market Share (%), By Drug, 2022
The development of novel treatment is anticipated to propel the global gastroparesis treatment market growth over the forecast period.
An increase in the prevalence of gastroparesis leads to an increase in the demand for novel treatment products. For instance, , in January 2018, according to National Institute of Diabetes and Digestive and Kidney Diseases, out of 100,000 people, about 10 men and about 40 women have gastroparesis in United States. Thus, developing newer products will create a lucrative opportunity for market players and drive the market growth. For instance, in November 2016, researchers at Emory University School of Medicine demonstrated the positive short-term outcomes for gastric per oral endoscopic pyloromyotomy or G-POEM, a minimally invasive procedure. The novel treatment showed significant improvement in symptoms of patients with gastroparesis (diabetic gastroparesis and idiopathic gastroparesis). Novel approaches/agents under evaluation for gastroparesis, include the prokinetic ghrelin agonist relamorelin, the prokinetic serotonergic agents velusetrag and prucalopride, the anti-emetic aprepitant, and per-endoscopic pyloric myotomy procedures.
Global Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
Global Gastroparesis Treatment Market: Restraint
Side effects associated with gastroparesis drugs are likely to hamper the market growth. Gastroparesis medications will vary in their side effects depending on the medication, dose, and patient’s other medical conditions. Fatigue, drowsiness, sedation, anxiety, and restlessness are some of the most prevalent side effects linked with prokinetics.
Major players operating in the global gastroparesis treatment market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.
Gastroparesis is a condition that affects the stomach muscles. It is a disease condition in which the stomach cannot empty itself of food in a normal manner. Nausea, vomiting, heartburn are the symptoms related to gastroparesis. It is most common in patients who have had diabetes for a long time and may also occur in other situations. Gastroparesis is caused due to viral infections, gastric (abdominal) surgery with injury to the vagus nerve, medications such as narcotics and some antidepressants, etc.
Strong promising pipelines developed by key players for gastroparesis treatment are anticipated to drive the gastroparesis treatment market growth. For instance, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced that the company received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A clinical trial study conducted by Processa Pharmaceuticals, Inc. for PCS12852 is in phase 2. PCS12852 is a 5-hydroxytryptamine 4 (5-HT4) receptor agonist. PCS12852 is indicated for the treatment of gastroparesis. Moreover, a surge in the number of patents for gastroparesis is likely to augment the market growth. For instance, in April 2018, EVOKE PHARMA, a specialty pharmaceutical company focused on the treatment of gastrointestinal (GI) diseases, announced that the European Patent Office issued a decision to Grant European Union (EU) patent no. 2747561 for Gimoti, covering formulations of metoclopramide for the intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis, specifically for women. In addition, strategies adopted by key players such as acquisition, partnership, etc. are likely to drive the market growth. For instance, in October 2016, Allergan a pharmaceutical company acquired Motus Therapeutics, a gastrointestinal disease subsidiary of Rhythm Holding Company, following positive phase 2b trial results of Motus’ investigational treatment of diabetic gastroparesis.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.